말초신경병증의 임상 척도 – 2021년 개정판

키워드

참고문헌 (61)

1. Dyck PJ, "Detection, characterization, and staging of polyneuropathy:assessed in diabetics", Muscle Nerve, 11, pp.21~32 (1988)
2. Dyck PJ, "Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy", N Engl J Med, 314, pp.461~465 (1986)
3. Dyck PJ, "The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests", Neurology, 41, pp.799~807 (1991)
4. Dyck PJ, "Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance", N Engl J Med, 325, pp.1482~1486 (1991)
5. Dyck PJ, "Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry", Ann Neurol, 8, pp.590~596 (1980)
6. Van den Berg-Vos RM, "Disease severity in multifocal motor neuropathy and its association with the response to immunoglobulin treatment", J Neurol, 249, pp.330~336 (2002)
7. Kleyweg RP, "Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome", Muscle Nerve, 14, pp.1103~1109 (1991)
8. Merkies IS, "Comparison between impairment and disability scales in immune-mediated polyneuropathies", Muscle Nerve, 28, pp.93~100 (2003)
9. Merkies IS, "Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies", Muscle Nerve, 23, pp.1393~1401 (2000)
10. Merkies IS, "Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) group", Neurology, 54, pp.943~949 (2000)
11. Merkies IS, "Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) group", Neurology, 53, pp.1648~1654 (1999)
12. Merkies IS, "Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies", J Neurol Neurosurg Psychiatry, 72, pp.596~601 (2002)
13. Feinstein AR, "Clinimetrics" (1987), Yale University Press
14. World Health Organization, "International classification of impairments, disabilities, and handicaps", WHO, ~ (1980)
15. World Health Organization, "International classification of impairments, disabilities, and handicaps", WHO, ~ (2001)
16. Bae JS, "Clinical scales for peripheral neuropathy", J Korean Neurol Assoc, 23(suppl 2), pp.4~15 (2005)
17. Dyck PJ, "Neuropathy symptom profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis", Neurology, 36, pp.1300~1308 (1986)
18. Dyck PJ, "Peripheral neuropathy", pp.686~697 (1994), W. B. Saunders Company
19. Meijer JW, "Symptom scoring systems to diagnose distal polyneuropathy in diabetes:the Diabetic Neuropathy Symptom score", Diabet Med, 19, pp.962~965 (2002)
20. Dyck PJ, "Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy", Brain, 108, pp.861~880 (1985)
21. Dyck PJ, "Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy", Diabetes Care, 10, pp.432~440 (1987)
22. Bril V, "NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy", Eur Neurol, 41(Suppl 1), pp.8~13 (1999)
23. Britland ST, "Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration", Diabetes, 39, pp.898~908 (1990)
24. Ochoa J, "Peripheral nerve disorders. Vol 2", pp.44~58 (1995), Butterworth-Heinemann
25. Boru UT, "Prevalence of peripheral neuropathy in type 2 diabetic patients attending a diabetes center in Turkey", Endocr J, 51, pp.563~567 (2004)
26. Haak ES, "The effect of alpha-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy", Microvasc Res, 58, pp.28~34 (1999)
27. Stamboulis E, "Axonal sensorimotor neuropathy in patients with beta-thalassaemia", J Neurol Neurosurg Psychiatry, 75, pp.1483~1486 (2004)
28. Omdal R, "Peripheral neuropathy in systemic lupus erythematosus", Neurology, 41, pp.808~811 (1991)
29. Sandberg GE, "Oral dryness and peripheral neuropathy in subjects with type 2 diabetes", J Diabetes Complications, 17, pp.192~198 (2003)
30. "Report and recommendations of the San Antonio conference on diabetic neuropathy. Consensus statement", Diabetes, 37, pp.1000~1004 (1988)
31. Feldman EL, "A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy", Diabetes Care, 17, pp.1281~1289 (1994)
32. Meijer JW, "Diabetic neuropathy examination: a hierarchical scoring system to diagnose distal polyneuropathy in diabetes", Diabetes Care, 23, pp.750~753 (2000)
33. Vallat JM, "Interferon beta-1a as an investigational treatment for CIDP", Neurology, 60, pp.S23~S28 (2003)
34. Federico P, "Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study", Neurology, 55, pp.1256~1262 (2000)
35. Hvas AM, "Vitamin B12 treatment normalizes metabolic markers but has limited clinical effect: a randomized placebo-controlled study", Clin Chem, 47, pp.1396~1404 (2001)
36. Salih AM, "Anti-ganglioside antibodies in patients with rheumatoid arthritis complicated by peripheral neuropathy", Br J Rheumatol, 35, pp.725~731 (1996)
37. Dyck PJ, "Longitudinal study of neuropathic deficits and nerve conduction abnormalities in hereditary motor and sensory neuropathy type 1", Neurology, 39, pp.1302~1308 (1989)
38. Dyck PJ, "The Rochester diabetic neuropathy study: reassessment of tests and criteria for diagnosis and staged severity", Neurology, 42, pp.1164~1170 (1992)
39. Van Asseldonk JT, "Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness", Brain, 126, pp.186~198 (2003)
40. Dyck PJ, "Peripheral neuropathy" (2005), WB Saunders Company
41. van Nes SI, "Revising two-point discrimination assessment in normal aging and in patients with polyneuropathies", J Neurol Neurosurg Psychiatry, 79, pp.832~834 (2008)
42. Chaudhry V, "A prospective study of suramin-induced peripheral neuropathy", Brain, 119(Pt 6), pp.2039~2052 (1996)
43. Chaudhry V, "Peripheral neuropathy from taxol and cisplatin combination chemotherapy:clinical and electrophysiological studies", Ann Neurol, 35, pp.304~311 (1994)
44. Cornblath DR, "Total neuropathy score: validation and reliability study", Neurology, 53, pp.1660~1664 (1999)
45. Cavaletti G, "Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale", Neurology, 61, pp.1297~1300 (2003)
46. Hartung HP, "Guillain-Barré syndrome, CIDP and other chronic immune-mediated neuropathies", Curr Opin Neurol, 11, pp.497~513 (1998)
47. Hughes RA, "Controlled trial prednisolone in acute polyneuropathy", Lancet, 2, pp.750~753 (1978)
48. "Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma exchange", sandoglobulin Guillain-Barré syndrome trial group, 1997, pp.349, 225~230
49. van der Meche FG, "A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barré study group", N Engl J Med, 326, pp.1123~1129 (1992)
50. Rosenfeld J, "Neuromuscular disorders in clinical practice", pp.309~343 (2002), Butterworth-Heinemann
51. Sharrack B, "Scale development and Guy's neurological disability scale", J Neurol, 246, pp.226~ (1999)
52. van Swieten JC, "Interobserver agreement for the assessment of handicap in stroke patients", Stroke, 19, pp.604~607 (1988)
53. Wade DT, "Measurements in neurological rehabilitation" (1992), Oxford University Press
54. Merkies IS, "Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies", Muscle Nerve, 25, pp.370~377 (2002)
55. "Influence of intensive diabetes treatment on quality-of-life outcomes in the diabetes control and complications trial", Diabetes Care, 19, pp.195~203 (1996)
56. Merkies IS, "Quality of life complements traditional outcome measures in immune-mediated polyneuropathies", Neurology, 59, pp.84~91 (2002)
57. Rosenstock J, "Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial", Pain, 110, pp.628~638 (2004)
58. Pfeiffer G, "Disability and quality of life in Charcot-Marie-Tooth disease type 1", J Neurol Neurosurg Psychiatry, 70, pp.548~550 (2001)
59. van Koningsveld R, "A clinical prognostic scoring system for Guillain-Barrésyndrome", Lancet Neurol, 6, pp.589~594 (2007)
60. Walgaard C, "Early recognition of poor prognosis in Guillain-Barrésyndrome", Neurology, 76, pp.968~975 (2011)
61. Walgaard C, "Prediction of respiratory insufficiency in Guillain-Barré syndrome", Ann Neurol, 67, pp.781~787 (2010)